Zoono Group Ltd represents a core set of values and a strong corporate philosophy. As a company, Zoono is committed to innovation, transparency, and sustainability. It values continuous improvement and strives to deliver high-quality products and services to its customers. Zoono Group Ltd believes in building strong relationships with stakeholders, including employees, customers, and partners, based on trust and mutual respect. The company's philosophy revolves around responsible business practices, ethical decision-making, and fostering a positive and inclusive work environment. Zoono Group Ltd aims to make a positive impact on society by providing effective and safe antimicrobial solutions.

Zoono Group Ltd is primarily present in several countries and regions worldwide. These include Australia, New Zealand, the United Kingdom, Europe, the United States, Canada, Asia, and the Middle East.

Zoono Group Ltd, a leading company in the antimicrobial industry, has achieved several significant milestones. Firstly, Zoono gained global recognition for its innovative and highly effective antimicrobial technology, which provides long-lasting protection against a wide range of pathogens. Additionally, the company successfully expanded its product range, catering to various industries including healthcare, consumer, and industrial sectors. Zoono Group Ltd also established strong partnerships with renowned organizations worldwide, enhancing its market presence and distribution capabilities. Furthermore, the company's shares have been listed on prestigious stock exchanges such as the Australian Securities Exchange (ASX) and the London Stock Exchange (LSE), providing investors with increased opportunities. Overall, Zoono Group Ltd has consistently demonstrated its commitment to pioneering antimicrobial solutions and achieving remarkable business growth.

Zoono Group Ltd is a leading company that specializes in the development and production of long-lasting antimicrobial solutions. Established in New Zealand, the company was founded in 2008 and has since expanded its operations globally. Zoono's innovative technology utilizes a unique bonding process that forms a protective barrier capable of eliminating a wide range of bacteria, viruses, and fungi. With a strong commitment to research and development, Zoono has continuously evolved its product offerings, including hand sanitizers, surface sprays, and other disinfecting solutions. Today, Zoono Group Ltd is recognized as a trusted provider of safe and effective antimicrobial protection worldwide.

The main competitors of Zoono Group Ltd in the market include companies such as Microban International, Clorox Company, Reckitt Benckiser Group plc, and 3M Company.

Zoono Group Ltd is primarily active in the industries of biotechnology, consumer goods, and healthcare.

The business model of Zoono Group Ltd revolves around the development, manufacture, and distribution of a range of antimicrobial solutions. Zoono Group focuses on creating and marketing innovative long-lasting disinfectant products for various applications, including commercial, industrial, and personal use. Their scientifically advanced formulations provide a protective barrier against harmful microbes, delivering extended germ protection. Zoono's products have gained recognition for their effectiveness, durability, and environmentally friendly features. As a leading company in the antimicrobial industry, Zoono Group Ltd continually strives to enhance their product portfolio and expand their global presence.

KGV kan i øjeblikket ikke beregnes for Zoono Group.

KUV kan i øjeblikket ikke beregnes for Zoono Group.

AlleAktien Kvalitetsscore for Zoono Group er 2/10.

Omsætningen kan i øjeblikket ikke beregnes for Zoono Group.

Overskuddet kan i øjeblikket ikke beregnes for Zoono Group.

The company Zoono Group Ltd is a specialist in antimicrobial technologies and offers products and services in various areas. The company is based in New Zealand and operates globally. Zoono's core business offers various antimicrobial solutions based on quaternary ammonium compounds and silver ions. These technologies effectively fight bacteria, viruses, and fungi, reducing the risk of infections. Zoono's business model involves developing, manufacturing, and distributing these technologies. One of Zoono's crucial sectors is the production of products for use in medicine. This includes antiseptic solutions for skin and hand disinfection, as well as wound disinfectants. These products are particularly crucial in hospitals and other medical facilities, where the spread of infections is a significant problem. Another important area in which Zoono operates is the food industry. This includes antimicrobial coatings for packaging and surfaces in food facilities to prevent the growth of bacteria and mold and extend the shelf life of food. Zoono also offers solutions for air and surface disinfection. Zoono's technologies can be used in ventilation systems, air conditioning, and rooms to reduce the spread of bacteria and viruses, thereby minimizing the risk of infection. Furthermore, Zoono offers products for personal use. This includes deodorants, mouthwashes, and hand sanitizers. These products are also intended for use by the general public and aim to reduce the overall risk of infection in society. Recently, the company has also begun to bring its antimicrobial technologies into the field of animal care. This includes antimicrobial dog protection products and products for disinfecting animal shelters and veterinary clinics. In summary, Zoono's business model involves developing, manufacturing, and distributing antimicrobial technologies. The company operates in various areas and sectors, including medicine, the food industry, air and surface disinfection, personal use, and animal care. By providing these products and services, Zoono helps reduce the risk of infection and improve the health and safety of humans and animals.

Zoono Group udbetaler et udbytte på 0 NZD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Zoono Group, eller selskabet udbetaler ikke udbytte.

ISIN'en for Zoono Group er AU000000ZNO4.

WKN for Zoono Group er A2PZCA.

Tickeren for Zoono Group er ZNO.AX.

I løbet af de sidste 12 måneder betalte Zoono Group en dividende på 0,03 NZD . Dette svarer til et dividendeudbytte på omkring 98,27 %. For de kommende 12 måneder vil Zoono Group sandsynligvis betale en dividende på 0 NZD.

Udbytteafkastet for Zoono Group er i øjeblikket 98,27 %.

Zoono Group betaler kvartalsvis udbytte. Dette uddeles i månederne .

Zoono Group betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 NZD. Dette svarer til et dividendeafkast på 0 %.

Zoono Group bliver tildelt sektoren 'Råmaterialer'.

For at modtage det seneste udbytte på Zoono Group fra den 21.9.2020 på 0,03 NZD, skulle du have haft aktien i din portefølje før ex-datoen den 4.9.2020.

Udbetalingen af det sidste udbytte blev foretaget den 21.9.2020.

I løbet af 2023 udbetalte Zoono Group 0 NZD i form af dividender.

Udbytterne fra Zoono Group udbetales i NZD.